News Sentiment

IONS sentiment intelligence

Ionis Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 54.39 Week of 17 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.6% over one week, -26.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Ionis Pharmaceuticals (IONS) Proxy filing Summary

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.6% Price reacting lower
Trend fit Trend inactive -26.6% over four weeks
Fair value 7.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 31
Negative 16

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
simplywall.st 9
Trefis 5
Business Wire 3
Quartr 2
Investing.com 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 14
Regulatory and legal 11
Analyst action 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Quartr Direct company coverage

Ionis Pharmaceuticals (IONS) Proxy filing Summary

Ionis Pharmaceuticals (IONS) has released its proxy filing summary for its annual meeting scheduled for June 4, 2026. Key proposals include the election of two directors, an advisory vote on executive compensation, and amendments to the 2011 Equity Incentive Plan and the 2000 Emp

Tone
Positive 67/100
Event
Market update
Published
19 Jul 2026 03:11
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com

This article from Investing.com announces a Form 4 filing for Ionis Pharmaceuticals Inc (IONS) on July 17th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securi

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 22:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Ionis Pharmaceuticals (IONS) awards 3,399 RSUs to board director Reikes

Ionis Pharmaceuticals Inc. (IONS) has granted 3,399 Restricted Stock Units (RSUs) to its board director, Peter N Reikes, as revealed in a recent Form 4 filing. These RSUs are part of the company's Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and will vest i

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 21:41
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis Pharmaceuticals director Ludwig Hantson reported a transaction in a Form 4 filing, acquiring 3,399 Restricted Stock Units (RSUs) on July 15, 2026. These RSUs, granted under the company's 2002 Non-Employee Directors' Stock Option Plan, will vest in three equal annual install

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 21:41
Source
Stock Titan
Trefis Direct company coverage

Ionis Pharmaceuticals Stock Slides 37% Over 7 Straight Down Days

Ionis Pharmaceuticals (IONS) stock has experienced a significant downturn, sliding 37% over seven consecutive trading days, resulting in a $5.2 billion loss in market value. This decline, which is specific to the company and not the broader market, is being attributed to the biot

Tone
Negative 16/100
Event
Market update
Published
17 Jul 2026 11:40
Source
Trefis
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

Pomerantz LLP is investigating Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following a significant stock drop. This investigation stems from the failure of their late-stage Phase-3 CARDIO-TTransform trial for Wainua to meet its primary endpoint, leading to a 23.9% share price decr

Tone
Negative 28/100
Event
Regulatory and legal
Published
16 Jul 2026 14:12
Source
PR Newswire
Trefis Direct company coverage

Ionis Pharmaceuticals Stock Slides 37% Over 6 Straight Down Days

Ionis Pharmaceuticals' (IONS) stock has fallen 36.6% over six consecutive trading days, reducing its market value by $5.2 billion to $9.0 billion. The biotech company shows operational strains with a -33.3% operating margin over the last twelve months, significantly lower than th

Tone
Negative 20/100
Event
Earnings
Published
16 Jul 2026 11:12
Source
Trefis
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Ionis Pharmaceuticals, Inc. (IONS) following a significant drop in its stock price. This decline occurred after Ionis disclosed that its late-stage Phase-3 CARDIO-TTransform trial for

Tone
Negative 15/100
Event
Regulatory and legal
Published
16 Jul 2026 11:00
Source
ACCESS Newswire
Investing.com Direct company coverage

Wolfe Research downgrades Ionis Pharmaceuticals stock rating

Wolfe Research downgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Peerperform, citing an overvalued stock price based on Fair Value calculations and potential risks related to competitor success and pipeline stagnation. Despite maintaining a consensus "Buy" rating

Tone
Negative 34/100
Event
Analyst action
Published
16 Jul 2026 07:12
Source
Investing.com
Investing.com Direct company coverage

Cathie Wood’s ARK sells AMD stock, buys Circle Internet Group and Ionis

Cathie Wood's ARK ETFs made significant portfolio adjustments on July 15, 2026. The firm notably purchased 220,012 shares of Circle Internet Group (CRCL) and 49,003 shares of Ionis Pharmaceuticals (IONS), while divesting 9,742 shares of Advanced Micro Devices (AMD) and continuing

Tone
Positive 66/100
Event
Market update
Published
15 Jul 2026 14:42
Source
Investing.com
GuruFocus Direct company coverage

Ionis Pharmaceuticals (IONS) to Discuss Q2 2026 Financial Performance in Live Webinar

Ionis Pharmaceuticals (IONS) will host a live webinar on July 15, 2026, to discuss its Q2 2026 financial results. The company, known for its RNA-targeted therapies, is currently considered about 2.4% overvalued by GuruFocus, with a GF Score of 72/100 indicating strong growth and

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 13:42
Source
GuruFocus
Trefis Direct company coverage

Ionis Pharmaceuticals Stock Slides 36% Over 5 Straight Down Days

Ionis Pharmaceuticals (IONS) stock has experienced a significant 36.4% cumulative loss over five consecutive trading days, wiping out $5.2 billion from its market value. Despite 47.5% revenue growth over the last twelve months, the biotech company struggles with profitability, sh

Tone
Negative 19/100
Event
Earnings
Published
15 Jul 2026 13:42
Source
Trefis
Pluang Direct company coverage

Pomerantz investigates Ionis Pharmaceuticals after trial failure causes 24% stock drop

Pomerantz LLP is investigating Ionis Pharmaceuticals following a 23.9% stock drop caused by the failure of its Phase-3 CARDIO-TTransform trial for Wainua. The law firm is looking into potential securities fraud or other unlawful practices by Ionis and its officers. Affected inves

Tone
Negative 14/100
Event
Regulatory and legal
Published
14 Jul 2026 22:45
Source
Pluang
FinancialContent Direct company coverage

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS | FinancialContent

Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals, Inc. (IONS) after the company announced its Phase-3 CARDIO-TTransform trial for Wainua failed to meet its primary endpoint. This news led to a significant 23.9% drop in Ionis's stock p

Tone
Negative 28/100
Event
Regulatory and legal
Published
14 Jul 2026 20:45
Source
FinancialContent
GlobeNewswire Direct company coverage

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

Ionis Pharmaceuticals (IONS) experienced a 23% stock drop after its late-stage trial for an experimental heart disease therapy, eplontersen, failed to meet its primary efficacy endpoint. This unexpected outcome has led the firm Hagens Berman to investigate whether Ionis was suffi

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 18:42
Source
GlobeNewswire
Stock Titan Direct company coverage

An investigational Alzheimer’s drug shows 50% slower decline on a cognition measure

Ionis Pharmaceuticals' partner, Biogen, presented Phase 2 CELIA data for diranersen, an investigational antisense oligonucleotide therapy for early Alzheimer’s disease. The study demonstrated meaningful clinical efficacy, with the 60 mg dose showing a 50% slower decline on the MM

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 13:41
Source
Stock Titan
Market source Direct company coverage

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

Ionis Pharmaceuticals (IONS) has commenced dosing the first patient in its phase I/II ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. This marks an important step in developing a potential disease-modifying treatment for the rare neurologica

Tone
Positive 67/100
Event
Regulatory and legal
Published
14 Jul 2026 13:41
Source
Market source
TradingView Direct company coverage

US462222AG5 Bond Profile — Key Metrics

This article provides key metrics for the US462222AG5 bond issued by Ionis Pharmaceuticals, Inc. It details the bond's issue date, maturity date, outstanding amount, face value, and coupon rate. The company profile highlights its focus on developing therapeutic drugs using antise

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 00:40
Source
TradingView
BioSpace Direct company coverage

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an RNA-targeted medicine for Dravet syndrome. ION337, developed with Ionis' advanced NMA technology, aims to be a disease-modifying therapy by increasing NaV1.1 protein production and

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 16:12
Source
BioSpace
grafa.com Direct company coverage

Ionis starts Dravet syndrome drug trial

Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. The trial will evaluate the drug's safety, tolerability, and dosing in children aged 2 to 12 years. ION337 utilizes Ionis'

Tone
Positive 72/100
Event
Regulatory and legal
Published
13 Jul 2026 15:40
Source
grafa.com
GuruFocus Direct company coverage

IONS Maintained by RBC Capital -- Price Target Lowered to $85.00

RBC Capital has maintained an "Outperform" rating for Ionis Pharmaceuticals (IONS) but lowered its price target from $100.00 to $85.00, reflecting a cautious outlook. The company's GF Value™ suggests it is currently 6.7% overvalued, while its GF Score™ of 72/100 indicates solid p

Tone
Negative 36/100
Event
Analyst action
Published
13 Jul 2026 15:12
Source
GuruFocus